NovoCure (NVCR) Shares Outstanding (Diluted Average) (2018 - 2026)

NovoCure's Shares Outstanding (Diluted Average) history runs 9 years deep, the most recent figure standing at $114.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 3.51% year-over-year to $114.1 million; the TTM figure through Mar 2026 stood at $114.1 million (up 3.51% YoY), while the FY2025 annual figure was $111.5 million, up 3.37% from the prior year.
• Shares Outstanding (Diluted Average) came in at $114.1 million for Q1 2026 at NovoCure, up from $111.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $114.1 million in Q1 2026 to a low of $104.2 million in Q1 2022.
• A 5-year average of $107.8 million and a median of $107.3 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• Across the five-year window, Shares Outstanding (Diluted Average) advanced 0.85% in 2024 and climbed 3.93% in 2025, its largest moves.
• NovoCure's Shares Outstanding (Diluted Average) stood at $104.7 million in 2022, then advanced by 1.65% to $106.4 million in 2023, then increased by 1.36% to $107.8 million in 2024, then advanced by 3.37% to $111.5 million in 2025, then rose by 2.4% to $114.1 million in 2026.
• According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $114.1 million, $111.5 million, and $111.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison